PT-141 (Bremelanotide) research guide for Salt. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
Research-Grade PT-141 (Bremelanotide) for Salt Investigators
PT-141 (Bremelanotide) isn't available on pharmacy shelves in Salt or virtually any local market — this is a specialist compound distributed through a dedicated online market. The benefit of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any physical store could provide. What genuinely separates top PT-141 (Bremelanotide) vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. What follows is a vendor evaluation and quality guide built specifically around PT-141 (Bremelanotide), covering everything a Salt researcher needs to source confidently.
PT-141 (Bremelanotide): What the Research Shows
The melanocortin receptor family (MC1R through MC5R) mediates a diverse range of physiological functions, and research peptides like Melanotan-2 and PT-141 (Bremelanotide) act on different receptor subtypes with different research applications. MT-2 has broad melanocortin receptor activity and has been studied for pigmentation (MC1R), appetite suppression (MC4R), and other endpoints. PT-141 is a more specific MC3R/MC4R agonist studied primarily for CNS-mediated effects. For researchers in Salt designing experiments with PT-141 (Bremelanotide), the specific receptor binding profile determines which outcomes are mechanistically attributable to the compound and which require additional explanation.
Where to Buy PT-141 (Bremelanotide) — A Researcher's Guide
Quality PT-141 (Bremelanotide) sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Vendors who do are signalling genuine quality commitment. When reviewing a PT-141 (Bremelanotide) COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. For Salt researchers evaluating new suppliers: a modest first purchase to test the product before committing to research quantities is the accepted approach among experienced researchers. Hold lyophilised PT-141 (Bremelanotide) at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order PT-141 (Bremelanotide) — ships to Salt
COA-verified · International tracking · Research grade
Research compound status for PT-141 (Bremelanotide) means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Reconstitute PT-141 (Bremelanotide) with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the PT-141 (Bremelanotide) COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no pricing advantage justifies skipping this verification. Researchers combining PT-141 (Bremelanotide) with other compounds should examine published studies for potential interaction data before beginning combination research.
Frequently Asked Questions
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
